Annexon Biosciences

Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor…

BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based…

<!-- Name:DistributionId Value:8845977 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients…

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients…

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients…

ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable…

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines…